Literature DB >> 12376754

Identification of two homologous antigenic peptides derived from L1 HPV-16 and 18 proteins specific for the HLA-B*3901 allele.

A Monroy-García1, B Weiss-Steider, J Hernández-Montes, V F Ortiz-Navarrete, A Bañuelos-Pánuco, A Acosta-Araujo, A Díaz-Quiñónez, C M López-Graniel, G Herbert, J Granados, C de Leo, R M Silva-López, M L Mora-García.   

Abstract

In this work we present evidence that the homologous peptides IHSMNSTIL and IHSMNSSIL derived from L1 HPV-16 and 18 proteins respectively, and with high specificity for the allele HLA-B*3901, according with an algorithm prediction program, induced T cell stimulation in patients with advanced cervical cancer positive for HPV-16 or 18 infection and for the HLA-B*3901 allele. Interestingly, T lymphocytes derived from a patient with HPV-18 infection and stimulated with the peptide IHSMNSTIL were capable to kill a cervical cancer cell line named Rova, derived from the tumor of the same patient. In addition, the cytotoxic activity was strongly increased when this cell line was previously treated with hrIFN-gamma. These results suggest that the CTL immune response to L1 HPV-16 and 18 protein derived epitopes is maintained in patients with advanced cervical cancer within specific alleles, and opens the possibility that homologous epitopes may be used in the generation of prophylactic vaccines for cervical tumors bearing different HPV-types.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376754     DOI: 10.1007/s00705-002-0854-y

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  4 in total

1.  Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Authors:  Stefania Bellone; Karim El-Sahwi; Emiliano Cocco; Francesca Casagrande; Marilisa Cargnelutti; Michela Palmieri; Eliana Bignotti; Chiara Romani; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

2.  Expression of MICA, MICB and NKG2D in human leukemic myelomonocytic and cervical cancer cells.

Authors:  Benny Weiss-Steider; Isabel Soto-Cruz; Christian A Martinez-Campos; Jorge Flavio Mendoza-Rincon
Journal:  J Exp Clin Cancer Res       Date:  2011-04-10

3.  Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid.

Authors:  María de Lourdes Mora-García; Alfonso Duenas-González; Jorge Hernández-Montes; Erick De la Cruz-Hernández; Enrique Pérez-Cárdenas; Benny Weiss-Steider; Edelmiro Santiago-Osorio; Vianney Francisco Ortíz-Navarrete; Víctor Hugo Rosales; David Cantú; Marcela Lizano-Soberón; Martha Patricia Rojo-Aguilar; Alberto Monroy-García
Journal:  J Transl Med       Date:  2006-12-27       Impact factor: 5.531

4.  Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1.

Authors:  John Lowe; Debasis Panda; Suzanne Rose; Ty Jensen; Willie A Hughes; For Yue Tso; Peter C Angeletti
Journal:  Virol J       Date:  2008-12-17       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.